Loading
Acute Kidney Injury / AZD4144 / Sepsis · Phase 2 Trial
ClinicalTrials.gov · September 2, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 randomized controlled trial of AZD4144 versus placebo in adults with sepsis-associated acute kidney injury, designed to measure 24-hour creatinine clearance as a surrogate of renal function. No results have been reported in this registry record; the trial is currently recruiting.
Phase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Sepsis, Acute Kidney Injury; age from 18 Years; to 80 Years. Intervention: Arm 1 (AZD4144). Compared with: Arm 2 (Placebo) — Placebo Comparator. n = 124. 74 sites across 14 countries.
This is a Phase 2 randomized controlled trial of AZD4144 versus placebo in adults with sepsis-associated acute kidney injury, designed to measure 24-hour creatinine clearance as a surrogate of renal function. No results have been reported in this registry record; the trial is currently recruiting.
Primary outcome is a surrogate marker (creatinine clearance); clinical endpoints such as mortality, renal recovery, or dialysis requirement are not specified as primary outcomes. Study is currently recruiting; efficacy, safety, and tolerability data are not yet available.
The source did not state who this applies to in practice.
Phase 2 interventional trial in a serious acute condition with surrogate renal endpoint; results not yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07215702). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 124 participants (ESTIMATED). Conditions: Sepsis, Acute Kidney Injury. Interventions: DRUG: AZD4144; DRUG: Placebo. Primary outcome measures: Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl). , During the treatment period.. Brief summary: This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.